ArticleEuropean journal of medical research2025
Long non-coding RNA EPB41L4A-AS1 as a biomarker of sepsis alleviates inflammatory response by targeting miR-146a-5p.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical value of LncRNA PAX8-AS1 as a biomarker for sepsis diagnosis and prognosis and its regulatory mechanism via the miR-34a-5p/HDAC1 axis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Research progress on the mechanism, diagnosis, and treatment of exosomal miRNA in chronic prostatitis.Frontiers in immunology · 2026Review
- Macrophage reprogramming and functional plasticity in sepsis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe prognosis of sepsis, a pathological condition associated with high mortality and rapid progression, can be improved with precise diagnosis, effective treatment, and nursing care. This study investigated the expression and clinical significance of the long non-coding RNA (lncRNA) EPB41L4A-AS1 in sepsis.
methodsThe serum EPB41L4A-AS1 levels in patients with sepsis were quantified using quantitative real-time polymerase chain reaction (RT-qPCR). The diagnostic value of EPB41L4A-AS1 was determined using the receiver operating characteristic curves. The correlation of EPB41L4A-AS1 with clinical parameters was evaluated using Pearson correlation. Kaplan-Meier assessment of prognostic value. Lipopolysaccharide (LPS)-treated THP-1 cells served as an in vitro cell model for sepsis. The mRNA and protein levels of inflammatory factors were examined using RT-qPCR analysis and enzyme-linked immunosorbent assay, respectively. Finally, the binding of EPB41L4A-AS1 to miR-146a-5p was determined using the dual-luciferase reporter and RNA immunoprecipitation assays.
resultsEPB41L4A-AS1 was significantly downregulated in patients with sepsis. The downregulation was inversely correlated with inflammatory cytokines and severity scores (APACHE II and SOFA). EPB41L4A-AS1 expression had a high diagnostic value in sepsis. The overexpression of EPB41L4A-AS1 downregulated inflammatory factor expression and release. However, miR-146a-5p mitigated the inhibitory effects of EPB41L4A-AS1 overexpression on inflammatory factors expression and release. EPB41L4A-AS1 was a target of miR-146a-5p.
conclusionlncRNA EPB41L4A-AS1 alleviates sepsis-related inflammation by targeting miR-146a-5p and may serve as a diagnostic biomarker for sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.